Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.

A growing number of studies have correlated higher urate levels with a lower risk of developing Parkinson's disease (PD) and with a favorable rate of disease progression, indicating that urate could be an important biomarker of the pathophysiology underlying PD. Dietary and genetic determinants of urate have also been linked to a reduced risk or delayed onset of PD. Based on the known antioxidant and metal complexing properties of urate, together with evidence for oxidative stress as a contributor to neurodegeneration in PD, urate may serve as an endogenous neuroprotectant that helps reduce the risk and rate of the disease. In this article we review the convergent biological, epidemiological and clinical data that identify urate as a promising biomarker of the risk, diagnosis and prognosis of PD.

[1]  P. Hochstein,et al.  Inhibition of free radical‐induced DNA damage by uric acid , 1984, FEBS letters.

[2]  E. Hirsch,et al.  Protection of midbrain dopaminergic neurons by the end‐product of purine metabolism uric acid: potentiation by low‐level depolarization , 2009, Journal of neurochemistry.

[3]  J. Kopec,et al.  Gout and the risk of Parkinson's disease: a cohort study. , 2008, Arthritis and rheumatism.

[4]  M. Mattson,et al.  Soluble Neuroprotective Antioxidant Uric Acid Analogs Ameliorate Ischemic Brain Injury in Mice , 2007, NeuroMolecular Medicine.

[5]  T. Nakagawa,et al.  Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. , 2002, Hypertension.

[6]  Bernard Thorens,et al.  Uric acid transport and disease. , 2010, The Journal of clinical investigation.

[7]  T. Byers,et al.  Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. , 1995, American journal of epidemiology.

[8]  O. Axelson,et al.  Nutritional and occupational factors influencing the risk of Parkinson's disease: A case‐control study in southeastern Sweden , 1999, Movement disorders : official journal of the Movement Disorder Society.

[9]  W. Nyhan.  Disorders of purine and pyrimidine metabolism. , 2005, Molecular genetics and metabolism.

[10]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[11]  D. Spiegelman,et al.  Plasma urate and Parkinson's disease in women. , 2010, American journal of epidemiology.

[12]  A. Shankar,et al.  Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community‐based survey , 2010, Movement disorders : official journal of the Movement Disorder Society.

[13]  T. Miura,et al.  Inhibitory effect of urate on oxidative damage induced by adriamycin-Fe3+ in the presence of H2O2. , 1993, Research communications in chemical pathology and pharmacology.

[14]  L. Hokkanen,et al.  Uric acid associates with cognition in Parkinson's disease. , 2008, Parkinsonism & related disorders.

[15]  M. Hernán,et al.  Alcohol consumption and the incidence of Parkinson's disease , 2003, Annals of neurology.

[16]  R. Anderson,et al.  Dopamine and Uric Acid Act as Antioxidants in the Repair of DNA Radicals: Implications in Parkinson's Disease , 2003, Free radical research.

[17]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Ågren,et al.  Brain energy metabolism and blood-brain barrier permeability in depressive patients: analyses of creatine, creatinine, urate, and albumin in CSF and blood. , 1984, Biological psychiatry.

[19]  P. Elliott,et al.  SLC2A9 Is a High-Capacity Urate Transporter in Humans , 2008, PLoS medicine.

[20]  S. Wiedmann,et al.  Association of Common Polymorphisms in GLUT9 Gene with Gout but Not with Coronary Artery Disease in a Large Case-Control Study , 2008, PloS one.

[21]  J. Hetta,et al.  Hypoxanthine, xanthine, urate and creatinine concentration gradients in cerebrospinal fluid. , 1988, Upsala journal of medical sciences.

[22]  P. Aisen,et al.  Plasma Urate and Progression of Mild Cognitive Impairment , 2008, Neurodegenerative Diseases.

[23]  D. Morens,et al.  Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. , 1994, American journal of epidemiology.

[24]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[25]  W. Willett,et al.  Alcohol intake and risk of incident gout in men: a prospective study , 2004, The Lancet.

[26]  M. Mcdermott,et al.  The relationship between uric acid levels and Huntington's disease progression , 2010, Movement disorders : official journal of the Movement Disorder Society.

[27]  D. Muzny,et al.  Two independent mutational events in the loss of urate oxidase during hominoid evolution , 2004, Journal of Molecular Evolution.

[28]  A. Hofman,et al.  Uric Acid Is a Risk Factor for Myocardial Infarction and Stroke: The Rotterdam Study , 2006, Stroke.

[29]  J. Kaye,et al.  Uric acid as a CNS antioxidant. , 2010, Journal of Alzheimer's disease : JAD.

[30]  K. Davies,et al.  Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. , 1986, The Biochemical journal.

[31]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[32]  L Zhang,et al.  Dietary factors and smoking as risk factors for PD in a rural population in China: a nested case–control study , 2006, Acta neurologica Scandinavica.

[33]  C. Tanner,et al.  Consumption of milk and calcium in midlife and the future risk of Parkinson disease , 2005, Neurology.

[34]  B. Halliwell,et al.  A Reassessment of the Peroxynitrite Scavenging Activity of Uric Acid , 2002, Annals of the New York Academy of Sciences.

[35]  Hyon K. Choi,et al.  Diet, urate, and Parkinson's disease risk in men. , 2008, American journal of epidemiology.

[36]  J. V. F. Valls,et al.  Estudio caso-control de marcadores de estrés oxidativo y metabolismo del hierro plasmático en la enfermedad de Parkinson , 2001 .

[37]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Michael J Thun,et al.  Consumption of dairy products and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[39]  J. Lowry,et al.  On the significance of brain extracellular uric acid detected with in-vivo monitoring techniques: a review , 1995, Behavioural Brain Research.

[40]  M. Hernán,et al.  A Prospective Study , 2007 .

[41]  M. Mattson,et al.  Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease , 2002, Journal of neurochemistry.

[42]  C. Tanner,et al.  Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.

[43]  W. H. Church,et al.  Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation , 1994, Brain Research Bulletin.

[44]  B F Becker,et al.  Oxidative stress in bacterial meningitis in humans , 2002, Neurology.

[45]  B. Halliwell,et al.  Inactivation of α1 ‐antiproteinase by hydroxyl radicals The effect of uric acid , 1989 .

[46]  P. Higgins,et al.  The Potential for Xanthine Oxidase Inhibition in the Prevention and Treatment of Cardiovascular and Cerebrovascular Disease , 2009, Cardiovascular Psychiatry and Neurology.

[47]  B. Halliwell,et al.  Action of biologically-relevant oxidizing species upon uric acid. Identification of uric acid oxidation products. , 1990, Chemico-biological interactions.

[48]  A. Wright,et al.  Variation in the Uric Acid Transporter Gene SLC2A9 and Its Association with AAO of Parkinson’s Disease , 2011, Journal of Molecular Neuroscience.

[49]  Hyon K. Choi,et al.  Pathogenesis of Gout , 2005, Annals of Internal Medicine.

[50]  L. Truong,et al.  A role for uric acid in the progression of renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[51]  V. Zissimopoulos,et al.  Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration , 2009, Clinical Neurology and Neurosurgery.

[52]  K. Murros,et al.  Low plasma uric acid level in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[53]  W. Nyhan,et al.  A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION. , 1964, The American journal of medicine.

[54]  H. Einsele,et al.  Effect of free radical scavengers and metal ion chelators on hydrogen peroxide and phenylhydrazine induced red blood cell lipid peroxidation. , 1987, Free radical research communications.

[55]  B. Zlokovic.  The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[56]  E. Orowan.  The Origin of Man , 1955, Nature.

[57]  A. Paganini-Hill.  Risk Factors for Parkinson’s Disease: The Leisure World Cohort Study , 2001, Neuroepidemiology.

[58]  F. Regoli,et al.  Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hydroxyl radicals. , 1999, Toxicology and applied pharmacology.

[59]  J. Kehrer.  The Haber-Weiss reaction and mechanisms of toxicity. , 2000, Toxicology.

[60]  A. Hofman,et al.  Serum uric acid levels and the risk of Parkinson disease , 2005, Annals of neurology.

[61]  J. Bart,et al.  Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.

[62]  V. Darley-Usmar,et al.  Nitrosation of Uric Acid by Peroxynitrite , 1998, The Journal of Biological Chemistry.

[63]  C. Mao,et al.  [Study on uric acid and the related factors associated with cognition in the patients with Parkinson's disease]. , 2009, Zhonghua yi xue za zhi.

[64]  M. Hediger,et al.  Molecular physiology of urate transport. , 2005, Physiology.

[65]  R. Petersen,et al.  No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[66]  J. Andersen,et al.  Oxidative and nitrative protein modifications in Parkinson's disease. , 2008, Free radical biology & medicine.

[67]  H. Tohgi,et al.  The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[68]  M. Weisskopf,et al.  Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[69]  Xuemei Huang,et al.  Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. , 2009, American journal of epidemiology.

[70]  S. Kish,et al.  Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[71]  William A. Richardson,et al.  SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout , 2008, Nature Genetics.

[72]  D. Guerrero,et al.  [Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease]. , 2001, Revista Española de Salud Pública.

[73]  M. Trevisan,et al.  Serum uric acid and hypertension: the Olivetti heart study. , 1994, Journal of human hypertension.

[74]  C. Burkhardt,et al.  Parkinson's disease: a chronic, low-grade antioxidant deficiency? , 1994, Medical hypotheses.

[75]  B. Miličić,et al.  Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood–brain barrier dysfunction , 2002, European journal of neurology.

[76]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[77]  D. Morens,et al.  Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. , 1996, American journal of epidemiology.

[78]  C. Knapp,et al.  Serum uric acid levels in optic neuritis , 2004, Multiple sclerosis.

[79]  Richard Simon,et al.  Development and Validation of Biomarker Classifiers for Treatment Selection. , 2008, Journal of statistical planning and inference.